Benefits of aflibercept treatment for age-related macular degeneration patients with good best-corrected visual acuity at baseline

Currently, age-related macular degeneration (AMD) is treated while patients exhibit good best-corrected visual acuity (BCVA). However, previous clinical trials only include patients with poor BCVA. We prospectively analyzed the benefits of intravitreal aflibercept (IVA) treatment for AMD patients ex...

Descripción completa

Detalles Bibliográficos
Autores principales: Minami, Sakiko, Nagai, Norihiro, Suzuki, Misa, Kurihara, Toshihide, Sonobe, Hideki, Kamoshita, Mamoru, Uchida, Atsuro, Shinoda, Hajime, Takagi, Hitoshi, Sonoda, Shozo, Sakamoto, Taiji, Tsubota, Kazuo, Ozawa, Yoko
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2018
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5758719/
https://www.ncbi.nlm.nih.gov/pubmed/29311612
http://dx.doi.org/10.1038/s41598-017-18255-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5758719/
https://www.ncbi.nlm.nih.gov/pubmed/29311612
http://dx.doi.org/10.1038/s41598-017-18255-4

Ejemplares similares